Edition:
United Kingdom

Basilea Pharmaceutica AG (BSLN.S)

BSLN.S on Swiss Exchange

68.10CHF
23 Feb 2018
Change (% chg)

CHF-0.60 (-0.87%)
Prev Close
CHF68.70
Open
CHF68.85
Day's High
CHF69.05
Day's Low
CHF67.55
Volume
61,649
Avg. Vol
66,519
52-wk High
CHF95.35
52-wk Low
CHF66.90

Chart for

About

Basilea Pharmaceutica AG is a Switzerland-based company engaged in the research, development and commercialization of pharmaceutical products. The Company focuses on pharmaceutical products in the therapeutic areas of bacterial infections, fungal infections and oncology. The Company has a range of drugs to treat drug-resistant... (more)

Overall

Beta: 1.31
Market Cap(Mil.): CHF947.87
Shares Outstanding(Mil.): 11.86
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 83.93 16.60
EPS (TTM): -- -- --
ROI: -- 1.66 10.66
ROE: -- 2.58 14.30

BRIEF-Basilea Pharmaceutica Reports Clinical Phase 3 Study Start With Antibiotic Ceftobiprole In Skin Infections

* REPORTS CLINICAL PHASE 3 STUDY START WITH ANTIBIOTIC CEFTOBIPROLE IN SKIN INFECTIONS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

23 Feb 2018

BRIEF-Basilea Appoints David Veitch As New CEO

* BASILEA'S CEO RONALD SCOTT WILL RETIRE. CHIEF COMMERCIAL OFFICER DAVID VEITCH NAMED AS SUCCESSOR. CHANGES IN THE BOARD OF DIRECTORS

21 Feb 2018

BRIEF-Basilea starts clinical phase 1 study in collaboration with U.S. Adult Brain Tumor Consortium ​

* ‍INITIATION OF A PHASE 1 STUDY CONDUCTED UNDER ITS CLINICAL STUDY AGREEMENT WITH ADULT BRAIN TUMOR CONSORTIUM IN U.S.​

03 Jan 2018

BRIEF-Basilea: Ceftobiprole Gets QIDP Designation From U.S. FDA

* BASILEA REPORTS THAT CEFTOBIPROLE RECEIVED QIDP DESIGNATION FROM U.S. FDA FOR THE TREATMENT OF STAPHYLOCOCCUS AUREUS BACTEREMIA (SAB) Source text for Eikon: Further company coverage: (Gdynia Newsroom)

21 Dec 2017

BRIEF-Basilea Extends Existing License Agreement With Pfizer For Cresemba

* BASILEA EXTENDS EXISTING LICENSE AGREEMENT WITH PFIZER FOR ANTIFUNGAL CRESEMBA® (ISAVUCONAZOLE) TO CHINA AND ASIA PACIFIC

01 Dec 2017

BRIEF-Basilea Pharmaceutica ‍marketing authorization for Cresemba for Switzerland​

* ‍MARKETING AUTHORIZATION RECEIVED FOR CRESEMBA FOR SWITZERLAND​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

02 Nov 2017

BRIEF-Basilea: Marc Engelhardt named new Chief Medical Officer

* BASILEA'S CHIEF MEDICAL OFFICER PROF. ACHIM KAUFHOLD TO RETIRE AND DR. MARC ENGELHARDT NAMED AS SUCCESSOR

31 Oct 2017

BRIEF-Basilea Pharmaceutica says ‍sales of antifungal cresemba in US exceeded threshold

* BASILEA PHARMACEUTICA - ‍SALES OF ANTIFUNGAL CRESEMBA IN US TRIGGER 1ST SALES MILESTONE PAYMENT FROM ASTELLAS PHARMA OF CHF 5 MILLION​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

23 Oct 2017

BRIEF-Basilea announces license with Shenzhen China Resources Gosun Pharmaceutical Co

* BASILEA ANNOUNCES LICENSE AGREEMENT FOR ANTIBIOTIC ZEVTERA® (CEFTOBIPROLE) WITH SHENZHEN CHINA RESOURCES GOSUN PHARMACEUTICAL CO., LTD. Source text for Eikon: Further company coverage: (Gdynia Newsroom)

28 Sep 2017

BRIEF-Cardiome announces agreement with Basilea

* Cardiome announces agreement with Basilea for distribution of Zevtera®/Mabelio® (Ceftobiprole) in Europe and Israel

12 Sep 2017

Earnings vs. Estimates